



Pluristem to Present at Global Scientific & Investment Conferences in December

HAIFA, ISRAEL, November 24, 2015 -- [Pluristem Therapeutics Inc.](#) (NasdaqCM/TASE: PSTI), a leading developer of placenta-based cell therapy products, today announced that members of its executive and scientific teams will present at the following conferences during the month of December:

[Florida Wealth Management & Family Office Conference 2015](#)

Date: December 1, 2015

Location: Miami Beach, Florida

Yaky Yanay, Pluristem's President, CFO and COO will deliver a corporate presentation.

[8th International Conference on Cachexia, Sarcopenia and Muscle Wasting](#)

Date: December 5, 2015

Location: Paris

Dr. Tobias Winkler of the Center for Musculoskeletal Surgery & Julius Wolff Institute Berlin, Charité, who served as Senior Scientist on Pluristem's completed Phase I/II orthopedic study, will present data from the trial. His presentation titled, "First in human allogeneic cell therapy after muscle trauma improves functional regeneration," will be delivered as part of the 'Late Breaking Clinical Trials & Trial Updates' session.

[Oppenheimer 26th Annual Healthcare Conference](#)

Date: December 8, 2015

Location: New York City

Karine Kleinhaus, MD, MPH, Pluristem's Divisional VP, North Americas, will deliver a corporate presentation.

[Israel Society for Biotechnology Engineering](#)

Date: December 13, 2015

Location: Tel Aviv

The following three poster presentations will be delivered:

- "The Process is the Product: A Novel Fully Automated, Controlled, Monitored and Scalable 2D Expansion System for Adherent Stromal Cells," presented by Pluristem's Development Team: Dotan Hoffman, Harel Kasuto, and Lior Raviv.

- “An Overview of the PLX Manufacturing Process, Highlighting Foundation Elements for Smart Scaling,” presented by Pluristem’s Development Team: Yonatan Levinson and Anna Zaretsky-Rits.
- “Bringing Cell Therapy Up to Patient Bed Side – The Development of an Automated and Controlled Point of Care Cell Thawing Device,” presented by Pluristem’s Development and Engineering Team: Lior Raviv, Anna Zaretsky-Rits, Dorina Roberman, Yoav Reut, and Anna Heymannieli.

Pluristem previously announced that on December 6, 2015, the Company’s Vice President of Research & Intellectual Property, Dr. Racheli Ofir, will present new data on PLX-R18 at the [American Society of Hematology’s Annual Meeting](#) in Orlando, Florida.

About Pluristem Therapeutics

Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cells release a cocktail of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring no tissue matching prior to administration.

Pluristem has a strong intellectual property position; Company-owned, GMP-certified manufacturing and research facilities; strategic relationships with major research institutions; and a seasoned management team.